4//SEC Filing
DAVIS JOHN C. JR 4
Accession 0001562180-19-006009
CIK 0001690585other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 4:03 PM ET
Size
14.2 KB
Accession
0001562180-19-006009
Insider Transaction Report
Form 4
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2019-12-10$9.49/sh+17,055$161,852→ 25,359 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-12-09−4,614→ 254,099 totalExercise: $9.49Exp: 2028-04-25→ Common Stock (4,614 underlying) - Sale
Common Stock
2019-12-10$15.00/sh−17,055$255,825→ 8,304 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-12-10−17,055→ 237,044 totalExercise: $9.49Exp: 2028-04-25→ Common Stock (17,055 underlying) - Exercise/Conversion
Common Stock
2019-12-09$9.49/sh+4,614$43,787→ 12,918 total - Sale
Common Stock
2019-12-09$15.00/sh−4,614$69,210→ 8,304 total
Footnotes (3)
- [F1]This trade is pursuant to an active 10b5-1 plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.
Documents
Issuer
Magenta Therapeutics, Inc.
CIK 0001690585
Entity typeother
Related Parties
1- filerCIK 0001741287
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 4:03 PM ET
- Size
- 14.2 KB